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Abstract: Background: Uveal melanoma is a disease that is distinct from cutaneous melanoma, with
a low tumor mutational burden and a 1-year overall survival of approximately 50% in patients with
metastatic uveal melanoma. Data showing a proven overall survival benefit with a systemic treatment
are lacking. Tebentafusp is a bispecific protein consisting of an affinity-enhanced T-cell receptor fused to
an anti-CD3 effector that can redirect T cells to target glycoprotein 100-positive cells. Methods: In this
open-label, phase 3 trial, we randomly assigned previously untreated HLA-A*02:01-positive patients with
metastatic uveal melanoma in a 2:1 ratio to receive tebentafusp (tebentafusp group) or the investigator’s
choice of therapy with single-agent pembrolizumab, ipilimumab, or dacarbazine (control group), stratified
according to the lactate dehydrogenase level. The primary end point was overall survival. Results: A
total of 378 patients were randomly assigned to either the tebentafusp group (252 patients) or the control
group (126 patients). Overall survival at 1 year was 73% in the tebentafusp group and 59% in the control
group (hazard ratio for death, 0.51; 95% confidence interval [CI], 0.37 to 0.71; P<0.001) in the intention-
to-treat population. Progression-free survival was also significantly higher in the tebentafusp group than
in the control group (31% vs. 19% at 6 months; hazard ratio for disease progression or death, 0.73; 95%
CI, 0.58 to 0.94; P = 0.01). The most common treatment-related adverse events in the tebentafusp group
were cytokine-mediated events (due to T-cell activation) and skin-related events (due to glycoprotein
100-positive melanocytes), including rash (83%), pyrexia (76%), and pruritus (69%). These adverse
events decreased in incidence and severity after the first three or four doses and infrequently led to
discontinuation of the trial treatment (2%). No treatment-related deaths were reported. Conclusions:
Treatment with tebentafusp resulted in longer overall survival than the control therapy among previously
untreated patients with metastatic uveal melanoma. (Funded by Immunocore; ClinicalTrials.gov number,
NCT03070392; EudraCT number, 2015-003153-18.).
DOI: https://doi.org/10.1056/nejmoa2103485





Nathan, Paul; Hassel, Jessica C; Rutkowski, Piotr; Baurain, Jean-François; Butler, Marcus O; et al;
Dummer, Reinhard (2021). Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.
New England Journal of Medicine, 385(13):1196-1206.
DOI: https://doi.org/10.1056/nejmoa2103485
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 385;13 nejm.org September 23, 20211196
The authors’ affiliations are listed in the 
Appendix. Address reprint requests to 
Dr. Nathan at the Mount Vernon Cancer 
Centre, Northwood HA6 2RN, United 
Kingdom, or at  p . nathan@ nhs . net.
*A complete list of investigators in the 
IMCgp100-202 trial is provided in the 
Supplementary Appendix, available at 
NEJM.org.
N Engl J Med 2021;385:1196-206.
DOI: 10.1056/NEJMoa2103485
Copyright © 2021 Massachusetts Medical Society.
BACKGROUND
Uveal melanoma is a disease that is distinct from cutaneous melanoma, with a low 
tumor mutational burden and a 1-year overall survival of approximately 50% in 
patients with metastatic uveal melanoma. Data showing a proven overall survival 
benefit with a systemic treatment are lacking. Tebentafusp is a bispecific protein 
consisting of an affinity-enhanced T-cell receptor fused to an anti-CD3 effector 
that can redirect T cells to target glycoprotein 100–positive cells.
METHODS
In this open-label, phase 3 trial, we randomly assigned previously untreated HLA-
A*02:01–positive patients with metastatic uveal melanoma in a 2:1 ratio to receive 
tebentafusp (tebentafusp group) or the investigator’s choice of therapy with single-
agent pembrolizumab, ipilimumab, or dacarbazine (control group), stratified accord-
ing to the lactate dehydrogenase level. The primary end point was overall survival.
RESULTS
A total of 378 patients were randomly assigned to either the tebentafusp group 
(252 patients) or the control group (126 patients). Overall survival at 1 year was 
73% in the tebentafusp group and 59% in the control group (hazard ratio for 
death, 0.51; 95% confidence interval [CI], 0.37 to 0.71; P<0.001) in the intention-
to-treat population. Progression-free survival was also significantly higher in the 
tebentafusp group than in the control group (31% vs. 19% at 6 months; hazard 
ratio for disease progression or death, 0.73; 95% CI, 0.58 to 0.94; P = 0.01). The 
most common treatment-related adverse events in the tebentafusp group were 
cytokine-mediated events (due to T-cell activation) and skin-related events (due to 
glycoprotein 100–positive melanocytes), including rash (83%), pyrexia (76%), and 
pruritus (69%). These adverse events decreased in incidence and severity after the 
first three or four doses and infrequently led to discontinuation of the trial treat-
ment (2%). No treatment-related deaths were reported.
CONCLUSIONS
Treatment with tebentafusp resulted in longer overall survival than the control 
therapy among previously untreated patients with metastatic uveal melanoma. 
(Funded by Immunocore; ClinicalTrials.gov number, NCT03070392; EudraCT number, 
2015 - 003153 - 18.)
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U
veal melanoma, the most common 
intraocular cancer in adults, represents 
approximately 3 to 5% of all melano-
mas.1 Although uveal melanoma arises from 
melanocytes, it is distinct from cutaneous mela-
noma, with different molecular drivers and meta-
static patterns and a different tumor-immune 
microenvironment.1-4 These differences are be-
lieved to contribute to a poor clinical response 
to systemic treatment, including immune check-
point inhibition.5,6 Up to 50% of patients with 
uveal melanoma will have metastases, which 
develop predominantly in the liver,7-10 and the 
prognosis in such patients is very poor; the me-
dian overall survival is approximately 1 year.6,11 
Data showing a survival benefit with systemic 
therapy are lacking.
Molecules termed immune-mobilizing mono-
clonal T-cell receptors against cancer (ImmTAC) 
are a new class of T-cell–redirecting bispecific 
fusion proteins that use an engineered high-
affinity T-cell receptor to target any protein, in-
cluding intracellular antigens, that is presented 
as a peptide–HLA complex on the target-cell sur-
face.12,13 Tebentafusp (formerly IMCgp100) consists 
of a soluble affinity-enhanced HLA-A*02:01–
restricted T-cell receptor that is specific for the 
glycoprotein 100 (gp100) peptide YLEPGPVTA 
and is fused to an anti-CD3 single-chain variable 
fragment. Once ImmTAC molecules are bound 
to their specific peptide–HLA complexes on the 
target-cell surface, they recruit and activate 
polyclonal T cells, through CD3, to release cy-
tokines and cytolytic mediators against target 
cells.12,14-16
In a single-group, phase 2 study involving 127 
patients with previously treated metastatic uveal 
melanoma, tebentafusp monotherapy showed 
more promising overall survival than historical 
controls.17 Traditional responses, as defined ac-
cording to Response Evaluation Criteria in Solid 
Tumors (RECIST), version 1.1, were observed, 
but this surrogate end point did not sufficiently 
predict long-term survival benefit. Clinical bene-
fit included indolent tumor growth and slow 
tumor shrinkage.18 In this multicenter, random-
ized, phase 3 trial, we compared tebentafusp with 
the investigator’s choice of treatment as first-




Patients were eligible for enrollment if they had 
local histologic or cytologic confirmation of meta-
static uveal melanoma, were at least 18 years of 
age, were HLA-A*02:01–positive (as are approxi-
mately 45% of persons in the United States and 
Europe), had received no previous systemic or 
liver-directed therapy for metastatic disease, had 
an Eastern Cooperative Oncology Group perfor-
mance-status score of 0 or 1 (on a 5-point scale, 
with higher scores indicating greater disability),19 
and had at least one measurable lesion, accord-
ing to RECIST, version 1.1.20 Patients were ex-
cluded if they had symptomatic central nervous 
system metastases, if they had active autoim-
mune disease for which they were receiving 
glucocorticoids, or if they were receiving sys-
temic immunosuppressive treatment. Full eligi-
bility criteria are provided in the Methods sec-
tions of the Supplementary Appendix and in the 
trial protocol, both of which are available with 
the full text of this article at NEJM.org.
Trial Design and Treatment
Patients were randomly assigned in a 2:1 ratio to 
receive tebentafusp (tebentafusp group) or the 
investigator’s choice of treatment with single-
agent pembrolizumab, ipilimumab, or dacarba-
zine (control group). Intrapatient dose escalation 
of tebentafusp had previously been shown to 
reduce toxic effects. Therefore, patients received 
intravenous tebentafusp at a dose of 20 µg on 
day 1, 30 µg on day 8, and 68 µg weekly there-
after. Patients were monitored overnight after 
treatment for the first 3 weeks during dose es-
calation. Pembrolizumab was administered intra-
venously at a dose of 2 mg per kilogram of body 
weight to a maximum of 200 mg per dose or 
(where approved locally) at a fixed dose of 200 mg 
on day 1 of each 21-day cycle. Ipilimumab was 
administered intravenously at a dose of 3 mg per 
kilogram on day 1 of each 21-day cycle for a 
maximum of four doses. Dacarbazine was ad-
ministered intravenously at a dose of 1000 mg 
per square meter of body-surface area on day 1 
of each 21-day cycle. Randomization was strati-
fied according to centrally assessed lactate dehy-
drogenase (LDH) status (LDH level higher than 
A Quick Take 
is available at 
NEJM.org
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the upper limit of the normal range [ULN] or 
LDH level less than or equal to the ULN).
Treatment (except for ipilimumab) was con-
tinued until the occurrence of radiographic pro-
gression, the development of unacceptable toxic 
effects, a decision by the investigator, or with-
drawal of consent by the patient. Patients who 
were receiving tebentafusp, pembrolizumab, or 
ipilimumab could continue with treatment be-
yond the time of initial RECIST-defined disease 
progression if they met prespecified criteria, as 
described in the Methods section in the Supple-
mentary Appendix. Subsequent therapy was de-
termined at the investigator’s discretion. Cross-
over between treatment groups was not permitted 
during the trial, in accordance with the original 
design of the trial. However, on the basis of the 
survival benefit observed at the first interim 
analysis, patients in the control group were sub-
sequently permitted to cross over to receive 
tebentafusp. Additional details regarding treat-
ment decisions, including management of adverse 
events, are provided in the protocol.
End Points and Assessments
The primary end point was overall survival as 
evaluated in a time-to-event analysis. On the 
basis of a phase 2 study that showed an associa-
tion between rash and survival,17 we performed 
a prespecified analysis of overall survival in pa-
tients in the tebentafusp group in whom a rash 
of any grade had developed within 1 week after 
initiation of tebentafusp treatment, as compared 
with all the patients in the control group. Sec-
ondary end points included disease control (de-
fined as complete response, partial response, 
or stable disease for ≥12 weeks, according to 
RECIST, version 1.1), objective response (defined 
as complete response or partial response, accord-
ing to RECIST, version 1.1), and progression-free 
survival as evaluated in a time-to-event analysis, 
and safety. All the secondary end points were 
assessed by investigators who were aware of the 
treatment assignment. Adverse events were as-
sessed by the investigator and were graded ac-
cording to the National Cancer Institute Com-
mon Terminology Criteria for Adverse Events, 
version 4.03, with the exception of cytokine re-
lease syndrome, which was evaluated and graded 
post hoc according to the 2019 recommenda-
tions of the American Society for Transplanta-
tion and Cellular Therapy (ASTCT) for consen-
sus grading for cytokine release syndrome.21 In 
this trial, rash was used as a composite term for 
a list of skin-related adverse events of any grade 
(Table S2 in the Supplementary Appendix).
Trial Oversight
The sponsor (Immunocore) and a steering com-
mittee designed the trial and analyzed the data, 
with the participation of all the authors. The 
protocol was approved by the institutional re-
view board or independent ethics committee at 
each center. The trial was conducted in accor-
dance with the principles of the Declaration of 
Helsinki and the International Council for Har-
monisation Good Clinical Practice guidelines. 
An independent data and safety monitoring com-
mittee provided oversight of efficacy and safety. 
The authors vouch for the accuracy and com-
pleteness of the data and for the fidelity of the 
trial to the protocol.
Statistical Analysis
The primary objectives were to evaluate overall 
survival in the tebentafusp group as compared 
with the control group in two analysis popula-
tions: the intention-to-treat population and the 
“rash analysis population.” The intention-to-treat 
population included all the patients who were 
randomly assigned to either group, and the rash 
analysis population included all the patients in 
the tebentafusp group in whom a rash had de-
veloped within the first week of treatment and 
all the patients in the control group. A 1-week 
interval for occurrence of rash was selected on 
the basis of previous clinical experience with 
tebentafusp and to limit the immortal time bias 
(i.e., the potential for bias in that patients must 
be alive to be assessed for rash). Progression-
free survival and best objective response were 
evaluated in the intention-to-treat population 
only. If the intention-to-treat analysis of overall 
survival showed statistical significance, these 
secondary end points were to be tested in a hier-
archical manner.
We estimated that a sample of 367 patients 
and the occurrence of 250 deaths would provide 
the trial with 89% power to show a significant 
survival advantage for tebentafusp in the inten-
tion-to-treat population, assuming a hazard ratio 
for death of 0.645 and using a two-sided alpha 
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level of 0.045. The survival distribution was as-
sumed to be exponential, with a median time to 
death of 12 months in the control group,6 and it 
was anticipated that 10% of the patients overall 
would withdraw from the trial. For the overall 
survival analysis in the rash analysis population, 
a two-sided alpha level of 0.005 was considered 
to be sufficient to provide the trial with 89% 
power to show an overall survival benefit, with 
the assumption that a rash would develop in 50% 
of the patients in the tebentafusp group during 
week 1 and that the hazard ratio for death would 
be 0.53.
We planned to perform two interim analyses 
after the occurrence of approximately 150 deaths 
and 200 deaths (60% and 80% of the anticipated 
deaths) in the intention-to-treat population. We 
used a Lan–DeMets alpha-spending function to 
calculate the O’Brien–Fleming stopping bound-
ary in order to adjust for variability in the actual 
number of events relative to the target number 
of events at the time of the interim analyses.22,23 
The timing of the interim analyses of overall sur-
vival in the rash analysis population coincided 
with the timing of the interim analyses of over-
all survival in the intention-to-treat population, 
and the Lan–DeMets alpha-spending function 
was again used to determine the stopping bound-
aries. For the first interim analysis of overall 
survival, the analysis in the rash analysis popu-
lation was to be performed first. If the results 
were found to be significant, then the full alpha 
from that analysis (0.005) could be carried over 
to the analysis in the intention-to-treat popula-
tion, which would result in an alpha level of 0.05 
for the intention-to-treat analysis. Taken together, 
the overall two-sided, experiment-wise type I 
error rate was preserved at 5% with the use of a 
combination of alpha splitting, hierarchical test-
ing, group-sequential design methods, and, if nec-
essary, the Maurer–Bretz graphical approach.24
Sensitivity analyses of efficacy and safety end 
points were performed in the safety population, 
which consisted of all the patients who had re-
ceived at least one dose of tebentafusp or the 
control treatment. Time-to-event estimates of 
overall survival and progression-free survival were 
calculated by the Kaplan–Meier method. The 
treatment groups were formally compared with 
the use of a log-rank test, stratified according to 
LDH status. Proportional-hazards assumptions 
were tested as proposed by Lin et al.25 If an as-
sumption was met, then treatment effects were 
characterized according to the hazard ratio de-
rived from a stratified Cox proportional-hazards 
regression model. In an ad hoc analysis of over-
all survival that evaluated the best response of 
stable disease and progressive disease according 
to treatment group, a landmark approach was 
used to address the immortal time bias, whereby 
overall survival was measured starting from day 
100 and patients were categorized on the basis 
of their best response by that time. Confidence 
intervals were not adjusted for multiplicity and 
therefore cannot be used to infer effects.
R esult s
Patients and Treatment
From March 2017 through June 2020, a total of 
442 HLA-A*02:01–positive patients were screened; 
of these patients, 378 were randomly assigned to 
either the tebentafusp group (252 patients) or 
the control group (126 patients) (Fig. S1). Among 
the 64 patients who were screened but did not 
undergo randomization, a majority (51) did not 
meet all the inclusion criteria or met at least one 
exclusion criterion. Among the patients in the 
control group, 103 (82%) received pembrolizu-
mab, 16 (13%) received ipilimumab, and 7 (6%) 
received dacarbazine. Demographic and clinical 
characteristics of the two groups were well bal-
anced at baseline (Table 1).
Among all the patients who had undergone 
randomization, 36% had an LDH level above the 
ULN, 5% had extrahepatic disease only, and the 
median time since the primary diagnosis was 
2.8 years, with no substantial difference between 
the groups in any of these variables. At the time 
of the clinical data cutoff for the first interim 
analysis (October 13, 2020), the median duration 
of follow-up was 14.1 months.
Overall Survival
At the data cutoff for the first interim analysis, 
150 deaths had occurred in the intention-to-treat 
population: 87 in the tebentafusp group and 63 
in the control group. The estimated overall sur-
vival at 1 year was 73% (95% confidence interval 
[CI], 66 to 79) in the tebentafusp group and 59% 
(95% CI, 48 to 67) in the control group; the es-
timated median duration of overall survival was 
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21.7 months (95% CI, 18.6 to 28.6) and 16.0 
months (95% CI, 9.7 to 18.4), respectively 
(Fig. 1A). The stratified hazard ratio for death 
was 0.51 (95% CI, 0.37 to 0.71; P<0.001) in favor 
of the tebentafusp group, and this treatment ef-
fect was generally observed across the prespeci-
fied subgroups (Fig. S2). For all results in which 
a hazard ratio is reported, the proportional-
hazards assumption was tested and verified.
Progression-Free Survival and Tumor 
Response
Treatment with tebentafusp resulted in a sig-
nificant progression-free survival benefit in the 
intention-to-treat population; at 6 months, the 
estimated progression-free survival was 31%, as 
compared with 19% in the control group (strati-
fied hazard ratio for disease progression or death, 
0.73; 95% CI, 0.58 to 0.94; P = 0.01) (Fig. 1B and 
Table S3). The percentage of patients who had an 
objective response was 9% (95% CI, 6 to 13) in 
the tebentafusp group and 5% (95% CI, 2 to 10) 
in the control group (Table S4). The median 
duration of response was similar in the two 
groups: 9.9 months in the tebentafusp group 
and 9.7 months in the control group. The per-
centage of patients who had disease control 
(complete response, partial response, or stable 
disease for ≥12 weeks) was higher in the teben-
tafusp group (46%; 95% CI, 39 to 52) than in the 
control group (27%; 95% CI, 20 to 36).
In a landmark-based analysis, among patients 
who had disease progression as the best re-
sponse before day 100, tebentafusp was associ-
ated with an estimated median duration of overall 
survival of 15.3 months (95% CI, 12.0 to not 
reached), as compared with 6.5 months (95% CI, 
4.9 to 13.4) in the control group (hazard ratio 
for death, 0.43; 95% CI, 0.27 to 0.68) (Fig. 2). 
This benefit appeared to be independent of prog-






Median age (range) — yr 64 (23–92) 66 (25–88)
Male sex — no. (%) 128 (51) 62 (49)
Median time since primary diagnosis (range) — yr 3.0 (0.1–25) 2.4 (0.1–36)
ECOG performance-status score — no. (%)†
0 192 (76) 85 (67)
1 49 (19) 31 (25)
2 0 1 (1)
Data missing 11 (4) 9 (7)
Lactate dehydrogenase >ULN — no. (%) 90 (36) 46 (37)
Largest metastatic lesion — no. (%)‡
≤3.0 cm, stage M1a 139 (55) 70 (56)
3.1 to 8.0 cm, stage M1b 92 (37) 46 (37)
≥8.1 cm, stage M1c 21 (8) 10 (8)
Location of metastasis — no. (%)
Hepatic only 131 (52) 59 (47)
Extrahepatic only 9 (4) 10 (8)
Hepatic and extrahepatic 111 (44) 55 (44)
Data missing 1 (<1) 2 (2)
Previous surgical therapy for metastatic disease — no. (%) 24 (10) 9 (7)
*  ULN denotes the upper limit of the normal range. Percentages may not sum to 100 because of rounding.
†  The Eastern Cooperative Oncology Group (ECOG) performance-status scale ranges from 0 to 5, with higher scores 
 indicating greater disability; a score of 0 indicates no symptoms, 1 mild symptoms, and 2 moderate symptoms.
‡  Lesions were assessed with the use of the seventh edition of the Cancer Staging Manual of the American Joint 
Committee on Cancer.
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nostic variables at baseline. Some patients had 
regression of some target lesions despite having 
a best response of disease progression; however, 
the overall survival benefit was also observed 
among patients who had no tumor shrinkage 
and only tumor growth as their best change 
while they were receiving treatment (Fig. S4). In 
addition, more patients in the tebentafusp 
group than in the control group had tumor re-
gression that did not meet the RECIST criteria 
for partial response (Fig. S3). In both groups, 
tumor regression was associated with longer 
overall survival.
Safety
The most common treatment-related adverse 
events of any grade in the tebentafusp group 
were cytokine-related adverse events, such as py-
rexia (76%), chills (47%), and hypotension (38%), 
and skin-related adverse events, such as rash 
(83%), pruritus (69%), and erythema (23%). Treat-
ment-related adverse events of grade 3 or 4 were 
reported in 109 patients (44%) in the tebentafusp 
group and in 19 patients (17%) in the control 
group (Table 2 and Tables S5 and S6). No treat-
ment-related deaths were reported in either 
group.
Figure 1. Overall Survival and Progression-free Survival in the Intention-to-Treat Population.
Shown are Kaplan–Meier estimates of overall survival (Panel A) and of progression-free survival (Panel B), according 
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In a majority of the patients in the tebentafusp 
group (57%), the treatment-related adverse events 
occurred in the first 4 weeks of treatment during 
intrapatient dose escalation; the incidence and 
severity of such events decreased with repeated 
dosing (Fig. 3). After 3 weeks of treatment, most 
of the patients transitioned to receive tebentafusp 
on an outpatient basis with no unacceptable 
toxic effects. Treatment-related adverse events of 
any grade in the control group reflected expect-
ed adverse effects of the therapies used. The per-
centage of patients who permanently discontinued 
the trial treatment owing to treatment-related 
adverse events was low in both groups: 2% in the 
tebentafusp group and 5% in the control group.
Cytokine release syndrome, as defined ac-
cording to the 2019 ASTCT criteria,21 occurred 
in 89% of the patients in the tebentafusp group 
(Table 2). Cytokine release syndrome, which was 
identified on the basis of the presence of pyrex-
ia, hypotension, and hypoxia, usually occurred 
within a few hours after the first three doses 
were administered. In most of the patients who 
were identified as having cytokine release syn-
drome, the maximum grade of this event was 
either grade 1 (12%) or grade 2 (76%). Few pa-
tients (1%) had grade 3 cytokine release syn-
drome, and no patient had cytokine release 
syndrome of grade 4 or 5. Although prophylactic 
glucocorticoids or other premedications were 
not mandated, patients who had cytokine release 
syndrome during the trial were usually treated 
with antipyretic agents, intravenous fluids, gluco-
corticoids, or a combination of these therapies.
The prespecified analysis of overall survival 
in the rash analysis population included 149 pa-
tients in the tebentafusp group in whom a rash 
of any grade had developed within 1 week of 
tebentafusp treatment, as compared with all 126 
patients in the control group. The estimated 
median overall survival was 27.4 months (95% 
CI, 20.2 to not reached) in the tebentafusp group 
and 16.0 months (95% CI, 9.7 to 18.4) in the 
control group (P<0.001). However, the presence 
of a rash during week 1 was found not to be an 
independent predictor of overall survival benefit, 
based on a multivariate Cox model that included 
patients who were randomly assigned to teben-
tafusp and that included known baseline prog-
nostic factors (Table S7).
The frequency of anti-tebentafusp antibodies 
was 29% (63 of 220 patients), and 6% of patients 
(13 of 220) had a decrease in the tebentafusp 
serum concentration. The development of anti-
Figure 2. Postlandmark Overall Survival in Patients with Best Overall Response of Stable Disease or Disease 
 Progression.
Shown are Kaplan–Meier estimates of overall survival in patients who had stable disease or disease progression as 
the best overall response before the landmark time point (day 100). The hazard ratio for death among patients who 
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tebentafusp antibodies had no effect on overall 
survival and was not associated with an increased 
risk of hypersensitivity reactions (Fig. S5 and 
Table S8).
Discussion
In this randomized, controlled, phase 3 trial 
involving HLA-A*02:01–positive patients with 
previously untreated metastatic uveal melanoma, 
treatment with tebentafusp resulted in signifi-
cantly longer overall survival than the investiga-
tor’s choice of treatment with pembrolizumab, 
ipilimumab, or dacarbazine. At the data cutoff 
for the first prespecified interim analysis, treat-
ment with tebentafusp had resulted in a relative 
risk of death that was 49% lower than that with 
the control therapy.
The decision to use the investigator’s choice 
of therapy for the control group reflects the fact 
that, to date, a proven standard treatment has 
not been established. Melanoma is generally re-
fractory to chemotherapy.11 In contrast to cuta-
neous melanoma, uveal melanoma has low tu-
mor mutational burden, which may partially 
explain the low sensitivity of uveal melanoma 
to checkpoint inhibitors.26 Recent single-group, 
phase 2 studies involving patients with uveal 
melanoma who were treated with ipilimumab 
plus nivolumab showed a 1-year survival of 52%27 






Any Grade Grade ≥3 Any Grade Grade ≥3
number of patients (percent)
Any treatment-related adverse event 243 (99) 109 (44) 91 (82) 19 (17)
Cytokine release syndrome† 217 (89) 2 (1) 3 (3) 0
Rash‡ 203 (83) 45 (18) 27 (24) 0
Pyrexia 185 (76) 9 (4) 3 (3) 0
Pruritus 169 (69) 11 (4) 23 (21) 0
Chills 114 (47) 1 (<1) 3 (3) 0
Nausea 105 (43) 2 (1) 21 (19) 0
Fatigue 101 (41) 7 (3) 29 (26) 1 (1)
Hypotension 93 (38) 8 (3) 0 0
Dry skin 72 (29) 0 4 (4) 0
Vomiting 64 (26) 1 (<1) 7 (6) 0
Erythema 56 (23) 0 1 (1) 0
Headache 53 (22) 1 (<1) 3 (3) 1 (1)
Aspartate aminotransferase increased 47 (19) 11 (4) 9 (8) 0
Alanine aminotransferase increased 43 (18) 7 (3) 8 (7) 2 (2)
Lipase increased 32 (13) 9 (4) 7 (6) 6 (5)
Diarrhea 31 (13) 2 (1) 16 (14) 3 (3)
Lymphopenia 22 (9) 6 (2) 2 (2) 0
Hyperbilirubinemia 21 (9) 5 (2) 2 (2) 0
Hypophosphatemia 19 (8) 7 (3) 1 (1) 0
Hypertension 15 (6) 9 (4) 2 (2) 1 (1)
*  Shown are treatment-related adverse event that were reported in at least 20% of patients (any grade) or in at least 2% 
of patients (grade ≥3) in either group.
†  Cytokine release syndrome was graded according to the 2019 recommendations of the American Society for Trans plan-
tation and Cellular Therapy for consensus grading for cytokine release syndrome.21
‡  Rash is a composite term for a list of skin-related adverse events of any grade (see Table S2).
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and 56%.28 These overall survival results overlap 
with those observed in the control group of the 
current trial (58%) as well as in recent meta-
analyses (52 to 56%)6,11; these findings confirm 
that the 1-year survival associated with ipilimu-
mab plus nivolumab is no better than that with 
the investigator’s choice of treatment used in the 
current trial. The 1-year overall survival with 
tebentafusp was 73% — a result that was higher 
than that reported for the combination of ipilimu-
mab and nivolumab.27,28
Tebentafusp is a bispecific protein that con-
sists of a soluble T-cell receptor fused to an anti-
CD3 single-chain variable fragment–activating 
domain. The high-affinity, high-specificity T-cell 
receptor targets a nine-amino-acid peptide that 
is derived from proteasomal degradation of the 
intracellular gp100 protein and that is presented 
by HLA molecules on the surface of target cells, 
including skin melanocytes and tumors derived 
from melanocytes.13 By targeting a specific shared 
tumor-associated antigen, these T-cell receptor 
bispecific molecules (in which one end binds 
cells bearing tumor peptide and the other end 
binds and activates T cells) can recruit T cells to 
target tumors independent of the presence of 
tumor antigen-specific T cells or of the tumor 
mutational status.
The progression-free survival benefit and 
the tumor response (as defined according to 
RECIST) of tebentafusp were both low in com-
parison with the magnitude of the survival bene-
fit. However, patients who received tebentafusp 
and had disease progression as the best response 
had longer survival than patients who had dis-
ease progression as the best response in the 
control group. This finding implies a clinically 
meaningful effect on outcomes for patients, 
even if a patient had no radiographically signifi-
cant decrease in tumor size. Although follow-up 
with respect to subsequent therapy remains im-
mature, the percentage of patients who received 
any subsequent therapy, including immunother-
apy, was generally similar in the two groups.
Further investigation will be needed to under-
stand the decoupling of RECIST-based radio-
graphic assessment and overall survival. Wheth-
er this observation is more broadly applicable to 
T-cell receptor bispecifics in other solid-tumor 
indications is unknown and also warrants fur-
ther study.
The safety profile of tebentafusp can be cat-
egorized into two major types of adverse events: 
cytokine-mediated events and skin-related events. 
Cytokine-mediated adverse events due to T-cell 
activation were reported in most of the patients, 
but a majority of the events were mild to moder-
ate in severity and were managed symptomati-
Figure 3. Incidence and Severity of Treatment-Related Adverse Events after Initial Doses of Tebentafusp.
Shown are the percentages of patients in the tebentafusp group who had treatment-related adverse events of grade 1 
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cally with standard treatment interventions. 
These events occurred in the hours after the first 
few doses; therefore, overnight monitoring of all 
the patients after the first three infusions was 
required. After this induction period, cytokine-
mediated adverse events decreased in incidence 
and severity, and the extension of overnight 
monitoring beyond that required by the protocol 
was uncommon.
The occurrence of skin-related adverse events, 
which were presumably due to the recognition of 
gp100-expressing melanocytes by tebentafusp, 
was also generally limited to the hours after 
administration of the first few doses. The onset 
of rash in the first week of treatment appeared 
to be associated with longer survival, which sug-
gests that the skin inflammation may be a sur-
rogate of activity against the tumor. However, 
the use of rash for clinical management deci-
sions is not appropriate, since rash is not an 
independent predictor of overall survival; most 
patients will have a rash at some point during 
treatment with tebentafusp, and some patients 
without a rash may also benefit. Overall, few 
patients discontinued treatment with tebentafusp 
owing to treatment-related adverse events, and 
no tebentafusp-related deaths were reported dur-
ing the trial.
Anti-tebentafusp antibodies developed in some 
patients, with minimal effect on the tebentafusp 
concentration and no apparent effect on either 
overall survival or the risk of hypersensitivity 
reactions. Whether the antibodies neutralize the 
effect of tebentafusp has not yet been deter-
mined.
In this randomized, phase 3 trial, treatment 
with tebentafusp, a soluble T-cell receptor and 
CD3-directed bispecific fusion protein, was as-
sociated with longer overall survival than the 
investigator’s choice of therapy in HLA-A*02:01–
positive patients with metastatic uveal melanoma.
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